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Abstract
Background: Chronic obstructive pulmonary disease (COPD) impairs physical status and impacts on mental health.
This prospective study was designed to assess associations between mental health and systemic biomarkers, and
their combined relationship with long-term survival in stable severe COPD.
Methods: Forty-five patients with severe but stable COPD (forced expiratory volume in 1 s of 29.8 (quartiles: 22.6; 41.4)
%predicted) were assessed using the Hospital Anxiety and Depression Scale (HADS), the Patient Health Questionnaire
(PHQ), St. George’s Respiratory Questionnaire and the State-Trait Anxiety Inventory (STAI). The following serum
biomarkers were measured: 25-OH-cholecalciferol, C-reactive protein, erythrocyte sedimentation rate, leucocyte
number, serum amyloid-A (SA-A), N-terminal pro-brain natriuretic peptide, troponin I, glycosylated haemoglobin,
haemoglobin (Hb), haematocrit (Hc), creatinine and thyroid-stimulating hormone. Patients were followed-up for
36 months. Associations between aspects of mental health and biomarkers, and their utility as predictors of 3-year
survival were evaluated by regression analyses.
Results: The prevalence of anxiety (HADS-A: 89.9 %), depression (HADS-D: 58.8 %; PHQ: 60.6 %), somatisation (PHQ-15:
81.8 %) and psychosocial stress (PHQ-stress: 60.6 %) was high. There was a significant positive association between the
leucocyte count and SA-A level with STAI-trait anxiety (p = 0.03 and p = 0.005, respectively), and between leucocytes
and PHQ-stress (p = 0.043). Hb and Hc were significantly negatively associated with HADS-depression (p = 0.041
and p = 0.031, respectively). Univariate Cox regression analyses revealed that leucocyte count (hazard ratio (HR)
2.976, 95 % CI 1.059-8.358; p = 0.038), and stress (HR 4.922, 95 % CI 1.06–22.848; p = 0.042) were linked to long-term
survival. In multivariate Cox regression analyses, including known risk factors for survival in COPD, PHQ-stress (HR 45.63,
95 % CI 1.72–1,208.48; p = 0.022) remained significantly associated with survival.
Conclusion: In this pilot study different dimensions of mental health were correlated to serum biomarkers, probably
reflecting systemic effects of COPD. While leucocyte number and PHQ-stress were associated with long-term survival in
univariate analyses, PHQ-stress remained in multivariate analyses as independent prognostic factor.
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Background
Chronic obstructive pulmonary disease (COPD) is a
systemic disease whose multiple dimensions are increas-
ingly uncovered by research. This has promoted the con-
cept of clinical phenotypes, which attempts to identify
specific subgroups of COPD patients with similar clinical
characteristics, treatment needs and prognosis [1]. As a
result, several clinical phenotypes, which can occur simul-
taneously, are assumed, e.g., patients with marked
hyperinflation, frequent exacerbations, rapid FEV1 decline,
metabolic and cardiovascular comorbidities, or eosino-
philic inflammation [1].
Importantly, COPD not only impairs physical status
but also has impacts on mental health [2–5]. Owing to
the prevalence of mental health problems in COPD
further evaluation is needed. Mental health involves vari-
ous aspects, such as psychiatric issues, somatisation and
disease-evoked psychological strain. Among these,
depression and anxiety are strongly related to worse
long-term outcome in COPD [6–8].* Correspondence: christianzilz@arcor.de1Department of Internal Medicine, HELIOS Hospital Munich-Perlach, Munich,
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Similarly, health-related quality of life (HRQOL) is a
broad multidimensional concept that usually includes
self-reported measures of physical and mental health [9],
and is also associated with long-term survival [10, 11]
and acute exacerbation [12].
Unfortunately, assessing mental health is time con-
suming and complex, because either an interview with
an experienced expert or complicated psychosocial
assessments with questionnaires are necessary. Further
problems lie in the quality of the completed question-
naires. Patients may have a poor compliance with regard
to mental health assessment via questionnaires, perhaps
due to misunderstanding, age-related diseases (e. g.,
cognitive or vision impairment) or lack of interest.
Clinically desirable would be an alternative approach in
assessing mental health, especially if it is independent
from the patient’s active cooperation, as well as easily to
obtain.
Serum biomarkers have been mostly explored in COPD
for estimating the risks of exacerbation and for long-term
monitoring [13], including procalcitonin [14], N-terminal
pro-brain natriuretic peptide (NT-ProBNP) and troponin
[15] for short-term assessment, and leukocyte number,
fibrinogen and CRP in relation to long-term survival [16],
as well as blood eosinophil count as biomarker for the
response to inhaled steroids [17].
Due to its systemic involvement, associations with
serum biomarkers could also occur regarding mental
health, particularly in severe COPD. Indeed, associations
between depression and the level of biomarkers, such as
C-reactive protein (CRP) [18], haemoglobin (Hb) [19],
thyroid-stimulating hormone (TSH) [20, 21] and vitamin
D [22–25], have been reported.
Based on these considerations, it seems plausible to
explore possible associations between mental health pa-
rameters and serum biomarkers. We therefore assessed
whether in stable severe COPD different dimensions of
mental health assessed via questionnaires correlated with
established serum biomarkers and whether they were
associated with long-term survival.
Methods
Study population
This prospective study included patients with COPD
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) stages III and IV, aged 35–95 years, admitted to
the Center for Pneumology at Donaustauf Hospital in a
clinically stable state between October 2009 and October
2010. Patients with a moderate to severe exacerbation
defined by a serum CRP level ≥20 mg/dl, a blood pH <7.35,
or having received antibiotic therapy within the last 2 weeks
were not included. Other exclusion criteria were acute
pneumonia confirmed by X-ray; lung resection; thoracic
deformations, or refusal to participate.
Eligible patients were enrolled at control appointments
for non-invasive intermittent positive pressure ventilation
or long-term oxygen therapy, and from new referrals to
the clinic. Demographic data, blood samples, physical
function, mMRC dyspnea scale, Cumulative Illness Rating
Scale-Geriatric and mental health (questionnaires) were
assessed after inclusion in the study; notification of death
during the study period (at least 36 months for each patient
after inclusion) was obtained from the patient’s relatives
or family doctor by telephone.
Blood samples
Peripheral blood samples were evaluated for the follow-
ing: leucocyte count, Hb level and the haematocrit (Hc)
(ABX Micros 60-CT analyser, equipped with v.1.0 soft-
ware, Horiba ABX, Montpellier, France); creatinine, CRP
and TSH levels (Dimension Xpand system, Dade Behring,
Schwalbach, Germany); glycosylated haemoglobin (HbA1c;
Cobas Integra 400 plus analyser, Roche Diagnostics
Deutschland GmbH, Mannheim, Germany); 25-OH-
cholecalciferol (25-OHD), serum amyloid-A (SA-A) and
troponin I (ADVIA Centaur TnI-Ultra assays, Bayer Vital
GmbH, Fernwald); NT-proBNP (Elecsys 2010 analyser,
Roche Diagnostics GmbH); and the erythrocyte sedimenta-
tion rate (ESR).
Functional analysis
Lung function assessment comprised post-bronchodilator
spirometry and body plethysmography performed using a
Masterlab system (Viasys Inc., Würzburg, Germany)
according to the recommendations of the American
Thoracic Society (ATS) [26]. The predicted values for
forced expiratory volume in 1 s (FEV1) and vital capacity
(VC) were calculated using the reference values determined
by the European Community for Steel and Coal [27].
A six-minute walk distance (6-MWD) test was
performed according to the recommendations of the
ATS [28]. The predicted 6-MWD was calculated using
age, gender, height and weight [29].
Mental health
Aspects of mental health were measured using the
German version of the Hospital Anxiety and Depression
Scale (HADS) [30], the Patient Health Questionnaire
(PHQ) [31], the St. George’s Respiratory Questionnaire
(SGRQ) [32] and the State-Trait Anxiety Inventory
(STAI) [33].
The HADS was originally developed as a screening
tool for anxiety and depression in an outpatient setting
but is now widely used in general hospital practice for
non-psychiatric clinical populations [30, 34]. It is com-
posed of a total of 14 questions on a questionnaire each
scored on a four-point Likert scale (0–3); there are seven
questions for symptoms of anxiety (HADS-A) and seven
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for symptoms of depression (HADS-D) each, therefore,
with a total score range of 0–21 [30]. Higher scores indi-
cate more severe symptoms [30]. The following categor-
ies (cut-off scores) for HADS-A and HADS-D were
used: no (0–7), borderline (8–10), severe (11–14) and
very severe (15–21).
The PHQ is a self-administered version of the Primary
Care Evaluation of Mental Disorders (PRIME-MD) and is
used in primary medical practice to determine psycho-
social and somatic stress factors as well as to screen for
the five most frequent psychiatric disease groups [31, 35].
The complete version comprises 78 questions to which
answers are evaluated with two-point to five-point Likert
scales, and one open question [31, 35]. In the present
study the modules of depression (PHQ-9) with nine items
(score range 0–27), somatic factors (PHQ-15) with 15
items (score range 0–30) and stress (PHQ-stress) with ten
items (score range 0–20) were used [36, 37]. Higher scores
indicate more severe symptoms [35–37].
As categories (cut-off scores) were used for PHQ-9:
no-minimal (0–4), mild (5–9), moderate (10–14) moder-
ate to severe (15–19) and severe (20–27); for PHQ-15:
no-minimal (0–4), low (5–9), medium (10–14) and high
(15–30), and for PHQ-stress: no-minimal (0–4), mild
(5–9), moderate (10–14) and severe (15–20). Depression,
somatisation and psychosocial stress were assumed for
scores ≥5.
The SGRQ was designed to measure disease-specific
health impairment in patients with chronic airflow limi-
tation. It consists of two parts and measures three
components (symptoms, activity and impact) and a total
score each with a score range of 0–100. Higher scores
indicate more limitations [32].
The STAI was developed to reveal state and trait anxiety
and is used in clinical and research settings. Two forms
are used, (X1-state (STAI-state) anxiety and X2-trait
(STAI-trait) anxiety), with 20 items each and a four-point
Likert scale. The scores can range from 20 to 80; higher
scores mean more anxiety [33].
Study approval
The study was approved by the ethics review committee
of the University of Regensburg, Germany (approval
number 09/097). Written informed consent was obtained
from the patients.
Statistical analysis
Continuous variables are shown as median values and
quartiles. Spearman’s rank correlation coefficient was used
to identify and measure the strength of the relationship
between biomarkers. Associations between biomarkers
and mental health were analysed using univariate linear
regression analyses, with mental health as a dependent
variable. Independent associations were assessed in an
adjusted multivariate linear analysis (method: enter).
Survival (until death from any cause) was analysed using
the Mann–Whitney U test, Cox proportional hazard
regression (univariate and, if applicable, multivariate) ana-
lyses, and Kaplan-Meier analyses (logrank test), starting by
the day of inclusion and ending after 3-years of follow up.
As cut-off we used median values. Variables significant in
univariate Cox proportional hazard regression analyses
and known risk factors for survival in COPD were entered
into multivariate Cox proportional hazard regression
analyses (method: stepwise backward likelihood ratio;
probability for stepwise entry/removal: 0.05/0.10) to iden-
tify independent predictors. P <0.05 were considered
statistically significant. SPSS version 20.0 (IBM SPSS
Statistics, USA) was used for the data analysis.
Results
Study population
At the screening 279 patients out of 621 (44.9 %)
showed GOLD stage III/IV. Among the 279 COPD
GOLD stage III/IV patients, 106 (38 %) had no interest
in participating, 86 (30.8 %) showed characteristics leading
to exclusion (exacerbations, acute pneumonia, antibiotic
therapy in the last 2 weeks, lung resection, thoracic defor-
mations, or neuromuscular disease), and 42 (15.1 %) did
not come to a scheduled visit (Fig. 1). Forty-five patients
were eligible for inclusion in the study, and their charac-
teristics are shown in Tables 1 and 2. No significant differ-
ences in patient characteristics were observed with respect
to gender, with the exception of nicotine consumption,
which was lower in females (32 (30; 50) vs. 53 (40; 80)
pack/years; p = 0.024).
Mental health
Not all patients completed the questionnaires sufficiently
(completed questionnaires: HADS, n = 34; PHQ, n = 33;
STAI, n = 33; and SGRQ, n = 35). However, no significant
differences were detected between patients who did or
did not. Furthermore, no significant differences in men-
tal health were found with regard to gender. The results
of all questionnaires are shown in Table 2.
HADS: anxiety and depression
Anxiety, demonstrated by the HADS-A score, was present
in 28 patients out of 34 (89.9 %); 13 patients out of 34
(38.2 %) showed borderline, 12 (35.3 %) severe, and 3
(8.8 %) very severe anxiety (Table 2, Fig. 2).
The prevalence of depression, demonstrated by the
HADS-D score, was 20 patients out of 34 (58.8 %); 10
patients out of 34 (29.4 %) had borderline, 8 (23.5 %)
severe, and 2 (5.9 %) had very severe depression.
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PHQ: depression, somatisation and stress
The scores of PHQ-9 (Fig. 3) indicated a depression rate
of 20 patients out of 33 (60.6 %). Mild depression was
apparent in 11 patients out of 33 (33.3 %); moderate in 3
(9.1 %); moderate to severe in 5 (15.2 %) and severe
depression in 1 (3 %). The somatisation rate, as demon-
strated by PHQ-15 scores, was 27 patients out of 33
(81.8 %), with low, medium and high somatic symptoms
split equally 9 patients out of 33 (27.3 %). The mild to
severe stress rate, as demonstrated by PHQ-stress
scores, was 20 patients out of 33 (60.6 %) with 14
patients out of 33 (42.4 %) mild cases, 5 (15.2 %) moder-
ate and 1 (3 %) severe.
SGRQ and STAI
Due to the lack of commonly established cut-off values
for SGRQ and STAI, only their median values are given
in Table 2.
Biomarkers
The results are presented in Table 2. SA-A was the only
biomarker showing differences between genders. Female
(n = 14) patients had higher values than male (n = 29)
patients (16.7 (7.5; 61.4) mg/l vs. 7.3 (3.6; 9.0) mg/l; p =
0.039). Correlations between biomarkers are demon-
strated in Tables 3 and 4.
Associations between mental health and serum
biomarkers
In univariate linear regression analyses, there were in-
verse associations between depression, demonstrated by
the HADS-D score, and the values for Hb (p = 0.041) or
the Hc (p = 0.031). Positive associations were found
between the PHQ-stress score and leucocyte numbers
(p = 0.043), as well as between the STAI-trait anxiety
score and leucocyte numbers (p = 0.03) or SA-A (p =
0.005) (Table 5). Because the Spearman’s rank correl-
ation was high between the significant biomarkers, they
were not included in a multivariate regression analysis.
Associations between mental health and functional
indices
Inverse associations were demonstrated between the
HADS-A score and VC (p = 0.01) and FEV1 (p = 0.015),
and between STAI-state anxiety and VC (p = 0.041).
Furthermore, positive associations were found between
the HADS-A score and residual volume/ total lung
capacity (p = 0.007). The 6-MWD score was negatively
linked to several aspects of mental health: HADS-A (p =
0.002), HADS-D (p = 0.031), somatisation demonstrated
by the PHQ-15 score (p = 0.021) and quality of life dem-
onstrated by the total score of the SGRQ (p = 0.003).
There was also an inverse association between the
HADS-A score and age (p = 0.045) (Table 5). In multivari-
ate linear regression analyses including significant bio-
markers and functional indices, the 6-MWD score
remained significant for HADS-A (p ≤ 0.024) and HADS-D
(p = 0.042) (Table 6).
Survival
Each patient was observed for 3 years. Within this
period 18 patients out of 45 (40 %) died; 9 patients
(50 %) died of respiratory, 2 (11.1 %) of non-respiratory,
and 7 (38.9 %) of not further specified causes.
The Mann–Whitney-U test did not demonstrate any
significant differences in the tested variables between
Fig. 1 Patients’ recruitment. Notes: Other exclusion reasons: acute pneumonia confirmed by X-ray; lung resection; thoracic deformations; C-reactive
protein (CRP) ≥20 mg/dl; blood pH <7.35; antibiotic therapy within the last 2 weeks. Abbreviations: NIPPV, non-invasive intermittent positive pressure
ventilation; LTOT, long-term oxygen therapy
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survivors and non-survivors. However, using the median
as cut-off in a Cox proportional hazard regression
model, leucocyte numbers (hazard ratio (HR) 2.97, 95 %
CI 1.06–8.36; p = 0.038) and PHQ-stress (HR 4.92, 95 %
CI 1.06–22.85; p = 0.042) were significantly linked to
long-term survival (Table 7 and Fig. 4). In multivariate
Cox regression analyses including known risk factors
for survival in COPD (6-MWD, body mass index, FEV1
(% predicted)) as well as PHQ-stress (model 1) and leu-
cocytes (model 2), only PHQ-stress (HR 45.63, 95 % CI
1.72–1,208.48; p = 0.022) remained significantly related
to survival, whereas leucocyte numbers did not (Table 7,
model 1 and 2).
Discussion
In this prospective study of patients with stable COPD
of GOLD stages III and IV we have examined the associ-
ation between mental health measures and serum bio-
markers by various statistical methods. Biomarkers and
mental health were also analysed for associations with
survival. There were statistically significant but rather
weak associations between some aspects of mental
health and SA-A, Hb, Hc and leucocyte number. Among
the mental health parameters analysed PHQ-stress and
among the biomarkers only leucocyte number were
associated with survival, whereas in an adjusted multi-
variate analysis only PHQ-stress remained as independ-
ent prognostic factor.
Mental health
We found that the prevalence of anxiety (HADS-A:
84.9 %) and depression (HADS-D: 58.8 %; PHQ-9:
60.6 %) was higher than reported in studies that
included patients in primary care with moderate to very
severe COPD of comparable age (Centers for Epidemio-
logic Studies Depression scale (severe COPD): 25 % [38];
HADS-A (cut-off ≥11; moderate to very severe COPD):
32.7 %, HADS-D: (cut-off ≥11; moderate to very severe
COPD): 20.8 % [39]). This was probably due to the
Table 1 Patient’s characteristics (n = 45)
Demographics
Age, years 64 (57; 72)
Male 31 (68.9)
Female 14 (31.1)
BMI, kg/m2 28.1 (6.8)
Smoking history
Active tobacco exposure, pack/years 50 (30; 70)
Current smoker 6 (13.3)
Ex-smoker 38 (84.4)
Never smoker 1 (2.2)
Spirometery
VC, % predicted 61.8 (50; 71.4)
FEV1, % predicted 29.8 (22.6; 41.4)
FEV1/FVC, % 45.5 (39; 53.3)
Blood gas analysisa
paO2, mmHg 62 (52.5; 73)
paCO2, mmHg 44 (40; 53.5)
BE, (mmol/l) 3.6 (1.45; 6.55)
pH 7.41 (7.39; 7.44)
mMRC dyspnea scaleb
Grade 0 3 (8.1)
Grade 1 1 (2.7)
Grade 2 5 (13.5)
Grade 3 9 (24.3)
Grade 4 19 (51.4)
Comorbidity- CIRS-G
Total scorec (0-56) 13 (10; 17)




LTOT and NIPPV 33 (73.3)
Only LTOT 8 (17.8)
Only NIPPV 2 (4.4)
Medications (selection)
Systemic corticosteroidse 15 (33.3)
Inhaled corticosteroids 37 (82.2)
LABA 37 (82.3)
SAMA 40 (88.9)
SABA and/or SAMA 31 (68.9)
Theophylline 18 (40)
Table 1 Patient’s characteristics (n = 45) (Continued)
Anxiolytics and/or antidepressants 19 (42.2)
Statins 13 (28.9)
Osteoporosis prophylaxis 17 (37.8)
BMI body mass index, CIRS-G Cumulative Illness Rating Scale-Geriatric, FEV1,
forced expiratory volume in I second, FVC forced vital capacity, LABA long-
acting beta-2 agonists, LAMA long-acting muscarinic antagonists, LTOT long-
term oxygen therapy, NIPPV non-invasive intermittent positive pressure
ventilation, SABA short-acting beta-2 agonists, SAMA short-acting muscarinic
antagonists, VC vital capacity
Data are expressed as the median (quartile) for continuous variables and as
frequencies (percentage) for categorical variables. awith a mean (±SD) oxygen
flow of 1.23 (±1.47) litres/min. bn = 37 due to poor patient compliance. csum of
the 14 or system disease items (each with a five-point Likert scales). dquotient
of total score and total number of items endorsed. ewith a median (quartile)
usage of 10 (5; 15) mg prednisolone daily
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selection, in our study, of patients with severe and very
severe COPD, and the inclusion of patients with border-
line anxiety and depression (HADS). Moreover, there
were also differences in the questionnaires used. When
we applied to our cohort the same HADS cut-off value
as used in previous reports (cut-off ≥11), the prevalence
of anxiety (46.7 %) and depression (29.4 %) was still
higher. The exclusion of patients categorised with mild
depression in the PHQ-9 (cut-off ≥10) gave a similar
depression rate of 27.3 %. The frequency of somatisation
(PHQ-15: 81.8 %) was also high in our study participants
in comparison to the general population (PHQ-15:
9.3 %) [40]. The stress score was also higher compared
to primary care patients of similar age (PHQ-stress
score: 6 vs. 2.3) [41] and showed an increased stress rate
(cut-off: ≥5) with 60.6 %. These results highlight the
importance of mental health and psychiatric diagnoses
particularly in patients with severe COPD, including the
view that COPD has to be recognized as systemic
disease that obviously has tremendous effects beyond
the somatic dimension.
Mental health and biomarkers
In our study, leucocyte number and the level of SA-A,
biomarkers particularly related to systemic inflamma-
tion, were significantly correlated with mental health. In
line with this finding, Justo and co-workers described
associations between a history of mental crisis and in-
flammatory markers (fibrinogen and leucocyte number)
in men [42]. Other investigators have reported associa-
tions between inflammation (defined by increased levels
of cytokines and CRP) and neuropsychiatric disease,
such as major depressive disease [43], generalised anx-
iety disorder [44], or even anxiety in healthy adults [45].
In accordance with this, Thompsen et al. demonstrated
that elevated leukocytes levels are associated with a
higher risk for comorbidities in COPD [46]. Prolonged
neuroinflammation, induced by pro-inflammatory cyto-
kines, is considered to play an important role in the
development of neurobehavioral impairment, dementia
and cognitive decline [29]. The inflamed brain micro-
environment apparently leads to an overactivation of
microglial cells with increased release of reactive oxygen
species that cause neurotoxicity [47], and to dysfunction
of central nervous system stem cells with resulting im-
pairment in tissue homeostasis and repair function [48].
These hypotheses has been recently supported by the
findings of Al-shair et al. [49] who described a strong
positive correlation between tumor necrosis factor-alpha
(TNF-α) and depression - measured by the Brief Assess-
ment Schedule Depression Cards (BASDEC) - in mainly
moderate and stable COPD patients [49]. TNF-α is an
inflammatory protein that has been shown to be in-
creased in stable COPD (compared to healthy control
Table 2 Characteristics of questionnaires and serological
biomarkers
Explanatory Variables n Median (quartiles)
Questionnaires:
HADS (0-21)
Anxiety 34 10 (8.75; 11)
Depression 34 8.5 (4; 11.3)
PHQ
Depression (0-27) 33 6 (3; 11)
Somatisation (0-30) 33 10 (6; 15)
Stress (0-20) 33 6 (3; 8)
SGRQ (0-100)
Total score 35 71.3 (57.5; 78.2)
Activity 35 85.9 (76.1; 92.5)
Impact 35 63.7 (42.5; 71.1)
Symptoms 35 69.2 (49; 76)
STAI (20-80)
State anxiety 33 45 (34,5; 54)
Trait anxiety 33 45 (36; 49,5)
Biomarkers:
Systemic inflammation:
25-OHD (nmol/l) 44 38.4 (25.3; 66.5)
CRP (mg/dl) 45 2.6 (1.1; 8.7)
ESR (mm/h) 33 17 (7.5; 40)
Leucocytes (103/μl) 45 9.7 (7.4; 12.4)
SA-A (mg/l) 43 8.1 (4; 17.8)
Cardiac dysfunction:
NT-proBNP (pg/ml) 45 176 (65; 300)
Troponin I (ng/ml) 45 0.013 (0.007; 0.02)
Other:
HbAIc (%) 45 6.2 (5.8; 6.9)
Hb (g/dl) 45 13.8 (13; 15.2)
Hc (%) 45 43 (40; 47)
Creatinine (mg/dl) 45 1.0 (0.8; 1.3)
TSH (mU/l) 45 0.8 (0.5; 1.2)
HADS cut-off scores: no (0-7), borderline (8-10), severe (11-14) and very severe
(15-21) anxiety (HADS-anxiety) or depression (HADS-depression). PHQ-9 cut-off
scores: no-minimal (0-4), mild (5-9), moderate (10-14) moderate to severe
(15-19) and severe (20-27) depression. PHQ-15 cut-off scores: no-minimal (0-4),
low (5-9), medium (10-14) and high (15-30) somatic factors. PHQ-stress cut-off
scores: no-minimal (0-4), mild (5-9), moderate (10-14) and severe (15-20)
psychosocial stress. For PHQ: Depression, somatisation and psychosocial stress
were assumed for scores ≥5. SGRQ and STAI: no commonly established cut-off
values. For all questionnaires: Higher scores indicate more limitations or more
severe symptoms
25-OHD 25-OH-cholecalciferol, CRP C-reactive protein, ESR erythrocyte sedi-
mentation rate, HADS Hospital Anxiety and Depression Scale, HbAlc glycosyl-
ated haemoglobin, Hb haemoglobin, Hc haematocrit, NT-proBNP N-terminal
pro-brain natriuretic peptide, PHQ Patient Health Questionnaire,
SA-A serum amyloid-A, SGRQ St. George’s Respiratory Questionnaire, STAI
State-Trait Anxiety Inventory, TSH thyroid-stimulating hormone
Zilz et al. Multidisciplinary Respiratory Medicine  (2016) 11:3 Page 6 of 12
groups) and seems to increase even more in acute
exacerbation of COPD [50]. As inflammatory mediator,
besides others, it induces acute phase proteins including
SA-A, which has been shown to be a more sensitive
marker of an acute exacerbation of COPD than CRP
alone or with dyspnea [51]. According to the present
study, SA-A seems to be also a sensitive marker for
negative effects on mental health in patients with stable
and severe COPD.
In addition, in our study lower Hb and Hc levels were
linked to higher depression values. Accordingly, we
found in a large retrospective analysis that in patients
with chronic respiratory failure, irrespective of the
underlying aetiology, anaemia was independently related
to dyspnoea and to a low HRQOL score when measured
by the Severe Respiratory Insufficiency questionnaire
[52]. Similar data were obtained by Cote and co-workers
who investigated 683 stable COPD out-patients and
found that anaemic patients showed a significantly
higher modified Medical Research Council dyspnoea
scale than non-anaemic patients [53]. In a post-hoc ana-
lysis of patients with COPD the physical function scores
of the HRQOL questionnaire Short Form-36 were
significantly lower in patients with anaemia compared to
those without [54].
Associations between mental health and functional data
We found significant negative correlations between 6-
MWD values and several dimensions of mental health.
The 6-MWD test is considered as an integrative meas-
ure influenced by physiological, physical and emotional
aspects [11], and there is evidence that HRQOL
increases with physical activity [55]. From this point of
view, our findings regarding 6-MWD appear to be
consistent with those of previous studies [56, 57].
Anxiety showed a negative linear association with
age. Cleland et al. found a similar association with
significantly higher anxiety and depression levels in
COPD patients below the age of 60 years [39]. This
was interpreted on the one hand due to a better
acceptance of symptoms in the elderly as a predictable
Fig. 2 Hospital Anxiety (a) and Depression (b) Scale (HADS)
Fig. 3 Patient Health Questionnaire (PHQ): scores of depression (a),
somatic symptoms (b) and psychosocial stress (c)
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late life stressor, and on the other hand as an indication
that in contrast to healthy subjects of the same age
younger COPD patients have to deal with functional
and physical impairment and therefore suffer more
psychologically [39].
Survival
Mental health in terms of PHQ-stress and systemic
inflammation in terms of leucocyte levels were signifi-
cantly related to 3-year survival in univariate survival
analysis. Regarding the predictive value of leukocytes
levels for long-term survival it appears reassuring that in
the large Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints (ECLIPSE) study, com-
prising 1843 COPD patients, leukocyte numbers im-
proved the predictive value of established risk factors
[16]. In contrast, in the present investigation the level of
serum CRP was not significantly linked to survival.
This is in line with the results of the study of de Torres
and co-workers who postulated that, particularly in
patients with moderate to severe COPD, the magnitude of
CRP-levels could be critically influenced by other factors
such as morbidity (cardiovascular disease, metabolic
syndrome, hypertension etc.), degree of physical
activity, diet, smoking status and medications [58].
Conversely, the prognostic value of CRP was higher
in large epidemiological studies covering patients with
less severe COPD [59].
In the present study, neither depression, nor anxiety has
shown to be associated with survival. Other studies re-
vealed depression as negative prognostic factor for mid- to
long-term survival (1 to 3 years) for COPD patients being
in a stable state of disease [6–8], and for short-term
survival (6 months) after recovering from an acute exacer-
bation [60]. Possible reasons for this differences might be
the use of different cut-off values, questionnaires and
observation time (Beck Depression Inventory: cut-off ≥19
[8], quintile of ≥15 compared with <5 [7]; Yesavage
depression score: cut-off 5 and 11 [6]; HADS-A/D: cut-off
≥8 [60]). Furthermore, anxiety was also no significant
predictor of mid- to long-term survival [7], but marginal
significant after acute exacerbation [60].
Table 3 Spearman’s rank correlation coefficient between biomarkers I
25-OHD (nmol/l) CRP (mg-dl) ESR (mm/h) Leucocytes (103/μl) SA-A (mg/l) NT-proBNP (pg/ml)
25-OHD (nmol/l) 1.00
CRP (mg/dl) 0.08 1.00
ESR (mm/h) 0.15 0.34 1.00
Leucocytes (103/μl) 0.15 0.18 0.07 1.00
SA-A (mg/l) 0.17 0.512** 0.22 0.593** 1.00
NT-proBNP (pg/ml) 0.06 0.14 −0.08 0.04 0.10 1.00
Troponin I (ng/ml) 0.00 0.12 0.10 0.18 0.11 0.493**
HbAlc (%) −0.01 0.28 0.415* 0.18 0.11 0 07
Hb (g/dl) −0.28 −0.25 −0.360* 0.02 −0.10 −0.05
Hc (%) −0.355* −0.19 −0.353* 0.06 −0.12 −0.04
Creatinine (mg/dl) −0.26 −0.07 0.11 0.04 0.00 0.355*
TSH (mU/l) −0.06 0.29 0.20 0.05 0.04 0.316*
*p = 0.05; **p = 0.01
25-OHD 25-OH-cholecalciferol, CRP C-reactive protein, ESR erythrocyte sedimentation rate, SA-A serum amyloid-A, NT-proBNP N-terminal pro-brain natriuretic
peptide, HbAlc glycosylated haemoglobin, Hb haemoglobin, Hc haematocrit, TSH thyroid-stimulating hormone
Highlighted in bold: p ≤ 0.05
Table 4 Spearman’s rank correlation coefficient between biomarkers II
Troponin I (ng/ml) HbAlc (%) Hb (g/dl) Hc (%) Creatinine (mg/dl) TSH (mU/l)
Troponin I (ng/ml) 1.00
HbAlc (%) 0.22 1.00
Hb (g/dl) 0.12 0.24 1.00
Hc (%) 0.19 0.27 0.946* 1.00
Creatinine (mg/dl) 0.432* 0.25 0.07 0.13 1.00
TSH (mU/l) −0.01 0.08 −0.19 −0.20 0.06 1.00
Notes: *p = 0.01
HbAlc glycosylated haemoglobin, Hb haemoglobin, Hc haematocrit, TSH thyroid-stimulating hormone
Highlighted in bold: p ≤ 0.05
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To the best of our knowledge, this is the first study to
investigate the PHQ-stress score and survival in patients
with COPD. Psychosocial stress occurs when the individual
recognises that environmental demands strain or exceed
their adaptive capability. Chronic psychosocial stress in
particular seems to influence the course of diseases, includ-
ing cardiovascular disease, upper respiratory infections,
autoimmune diseases, diabetes and depression [61]. This is
in line with our findings of an association of increased psy-
chosocial stress levels and mortality in severe COPD.
Moreover, sleep is a vital counterbalance to stress enabling
the body to recover and is essential for coping with stress
[62]. Therefore, a disease such as COPD, with its high
prevalence of sleep disturbance, is at risk of causing in-
creased stress. Chronic psychosocial stress also can lead to
glucocorticoid receptor resistance and consequently inter-
feres with the control of inflammation [63], which could
also explain its positive linear correlation with leucocyte
numbers.
Table 5 Linear univariate regression analysis of the
questionnaire dimensions
Explanatory Variable B Slope (95 % CI) p*
Univariate analyses
HADS anxiety
Age (years) −0.11 (-0.217-(-0.002)) 0.045
VC (%) −0.06 (-0.104-(-0.015)) 0.01
FEV1 (%) −0.1 (-0.174-(-0.02)) 0.015
6-MWD (%) −0.09 (-0.136-(-0.035)) 0.002
RV/ TLC 0.042 (0.012-0.072) 0.007
HADS depression
Hb (g/dl) −0.94 (-1.838-(-0.041)) 0.041
Hc (%) −0.3 (-0.577-(-0.029)) 0.031
6-MWD (%) −0.12 (-0.234-(-0.012)) 0.031
PHQ-15 (somatisation)
6-MWD (%) −0.15 (-0.276-(-0.025)) 0.021
PHQ-stress
Leucocytes (103/μl) 0.4 (0.013-0.777) 0.043
SGRQ-total
6-MWD −0.44 (-0.714-(-0.166)) 0.003
STAI-state anxiety
VC (%) −0.23 (-0.453-(-0.01)) 0.041
STAI-trait anxiety
Leucocytes (103/μl) 1.1 (0.1117-2.089) 0.03
SA-A (mg/l) 0.17 (0.055-0.276) 0.005
*Only the significant (p ≤ 0.05) variables are shown. The questionnaire
dimensions were the dependent variables
6-MWD, six-minute walk test, ESR erythrocyte sedimentation rate, FEV1, forced
expiratory volume in 1 s, Hb haemoglobin, Hc haematocrit, SA-A serum
amyloid-A, RV residual volume, TLC total lung capacity, VC vital capacity, HADS
Hospital Anxiety and Depression Scale, PHQ Patient Health Questionnaire, SGRQ
St. George’s Respiratory Questinnaire, STAI State-trait anxiety inventory
Table 6 Multivariate linear regression analysis of the
questionnaire dimensios
Explanatory Variable Slope (95 % Cl) p Model R2
HADS Anxiety
RV/TLC 0.02 (-0.017-0.056) 0.272
6-MWD (%) −0.072 (-0.128-(-0.016)) 0.014 0.401
VC (%) −0.027 (-0.090-0.037) 0.391
6-MWD (%) −0.078 (-0.132-(-0.024)) 0.024 0.394
FEV1 (%) −0.079 (-0.124-0.065) 0.519
6-MWD (%) −0.030 (-0.135-(-0.024)) 0.008 0.384
HADS Depression
6-MWD (%) −0.111 (-0.227-0.005) 0.059
Hc (%) −0.168 (-0.600-0.265) 0.429 0.228
6-MWD (%) −0.111 (-0.228-(-0.005)) 0.042
Hb (g/dl) −0.635 (-1.917-0.646) 0.314 0.243
25-OHD 25-OH-cholecalciferol, 6-MWD six-minute walk test, ESR erythrocyte
sedimentation rate, FEV11 forced expiratory volume in 1 s, Hb haemoglobin, Hc
haematocrit, RV residual volume, SA-A serum amyloid-A, TLC total lung capacity,
VC vital capacity, HADS Hospital Anxiety and Depression Scale, STAI State-trait
anxiety inventory. Questionnaire dimensions were the dependent variables
Highlighted in bold: p ≤ 0.05
Table 7 Cox regression analysis of survival according to
categorisation of variables < vs. > the median value
Explanatory Variable HR (95 % CI) *p
Univariate analysis
PHQ-stress 4.92 (1.06-22.85) 0.042
Leucocytes 2.97 (1.06-8.36) 0.038
6-MWD (%) 2.07 (0.6-7.07) 0.248
BMI 0.77 (0.30-1.95) 0.58
FEV1, % predicted 1.51 (0.59-3.89) 0.395
Multivariate analyses
Model I
6-MWD (%) 19.58 (1.01-380.75) 0.049
BMI 48.73 (1.21-1969.65) 0.039
FEV1, % predicted 3.37 (0.35-32.55) 0.295
PHQ-stress 45.63 (1.72-1,208.48) 0.022
Model 2
6-MWD (%) 2.6 (0.71-9.57) 0.151
BMI 1.34 (0.38-4.79) 0.650
FEV1, % predicted 1.03 (0.25-4.18) 0.970
Leucocytes 3.41 (0.91-12.85) 0.069
*Only the significant (p ≤ 0.05) univariate variables for physical function,
demographic data and biomarkers are shown. Model 1 and 2: Cox
proportional hazard model (method: stepwise backward likelihood ratio)
including known risk factors for survival in COPD (6-MWD, body mass index,
FEV1, (% predicted)) as well as PHQ-stress (model 1) and leucocytes (model 2)
PHQ Patient Health Questionnaire, &-MWD six-minute walk test, BMI body
mass index, FEV1 forced expiratory volume in 1 s
Highlighted in bold: p ≤ 0.05
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Limitations
Firstly, the small sample size allowed detecting only rela-
tively strong associations, and limited statistical power
especially for multivariate analyses. Secondly, the pa-
tients’ motivation to start and to complete the question-
naires apparently dwindled with the number of pages.
Fewer questionnaires would have increased motivation
and compliance. Thirdly, not all questionnaires have an
accepted score classification; therefore, the use of median
values was the simplest way for comparison. It is, there-
fore, possible that associations would be different using
other classification systems. Fourthly, corticosteroids
(systemic and/or inhaled) and statins might influence
especially inflammation markers like CRP, leucocyte
numbers and SA-A; osteoporosis prophylaxis might affect
the level of 25-OHD, and anxiolytics, antidepressants,
morphine/morphine derivates, corticosteroids and theo-
phylline the questionnaire results. Finally, the seemingly
paradoxical tendencies regarding survival and lung func-
tion or 6-MWD suggest that we had to deal with a specific
selection of patients. In view of this it seems of even
greater interest that psychosocial stress was a predictor for
survival even in patients with a tendency towards pro-
longed survival despite worse lung function or 6-MWD.
Conclusion
In conclusion, the different dimensions of mental health
assessed in this pilot study were related to serum bio-
markers although these associations were rather weak.
This might be indicative of the heterogeneity of the dis-
ease. Regarding the predictive value for long-term survival,
the PHQ-stress score was an independent prognostic fac-
tor in multivariate analyses, whereas among biomarkers,
only leukocyte numbers showed an association and only
in univariate analysis. The observation that psychosocial
stress had a greater prognostic value than conventional
biomarkers suggests that this easily measured parameter
would be useful in the prognostic assessment of patients
with severe COPD and – with regard to the multiple
systemic effects - probably should be included in the
assessment of COPD.
This pilot study may help to design further larger
prospective trials to investigate the associations between
mental health, serum biomarkers and survival in severe
COPD in more detail.
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